Welcome to our dedicated page for ONXEO news (Ticker: ONXEO), a resource for investors and traders seeking the latest updates and insights on ONXEO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONXEO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONXEO's position in the market.
Onxeo, a clinical-stage biotechnology company focused on tumor DNA Damage Response (DDR), announced the publication of its 2020 annual financial report, available here. The company is developing innovative oncology drugs, including AsiDNA, a clinical-stage candidate in combination trials, and OX401, a next-generation PARP inhibitor undergoing preclinical studies. Onxeo aims to transition compounds from research to clinical proof-of-concept, enhancing its partnership attractiveness.
Onxeo S.A. has appointed
Onxeo reported its fiscal year 2021 results, revealing revenues of €4.1 million, a decrease from €4.8 million in 2020. The net loss widened to €5.9 million from a profit of €1.1 million, attributed to stable operating expenses of €9.7 million, primarily from clinical developments. Cash position improved to €17.9 million, aided by €12 million financing from stakeholders. This funding extends financial visibility to Q2 2023. Onxeo focuses on advancing its lead product, AsiDNA, in various clinical trials while developing OX400 compounds and optimizing its strategic approach.
Onxeo announces new preclinical data for AsiDNA™ ahead of its presentation at the AACR Annual Meeting 2022 from April 8-13, 2022. The findings demonstrate that AsiDNA™ can effectively prevent resistance to tyrosine kinase inhibitors in lung cancer models, showcasing a potential therapeutic avenue. Additionally, it protects healthy cells from the toxic effects of various anti-cancer treatments while enhancing DNA repair in healthy cells. The oral session is set for April 10, and a poster session for April 12, confirming AsiDNA™'s promising role in oncology.
Onxeo S.A., a clinical-stage biotechnology company, presented new preclinical data at the
Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), a biotechnology company focused on innovative oncology drugs, has announced its financial agenda for 2022. Key dates include: Full-year 2021 results on March 30, 2022; Shareholders’ general meeting on May 12, 2022; and Half-year 2022 results on July 28, 2022. Onxeo specializes in therapeutic agents for DNA Damage Response (DDR) in rare and resistant cancers, with promising compounds like AsiDNA™ and OX401 in its pipeline.
On December 31, 2021, ONXEO (ALONX) reported liquidity account resources as part of its contract with Kepler Cheuvreux. The account held 429,850 shares and €36,891.92. For the semester, there were 256 buy-side executions involving 357,510 shares and €179,383.26, alongside 155 sell-side executions for 221,580 shares and €115,071.34. In comparison, on June 30, 2021, the account had 293,920 shares and €101,406.22. The report complies with AMF Decision N°2021-01, which renews liquidity contracts as an accepted market practice.
Onxeo S.A. has appointed Julien Miara as interim CEO, effective January 3, 2022. Miara, with over 10 years in finance and biotechnology, aims to ensure the company aligns with its strategic plan during the CEO transition. The Board is also seeking a permanent CEO to expedite the development of AsiDNA and enhance international visibility. The company focuses on innovative oncology drugs targeting tumor DNA Damage Response, with promising studies ongoing for AsiDNA™ and OX401.
Onxeo S.A. (Euronext: ALONX, ONXEO) presented new preclinical data at the EACR-AstraZeneca Virtual Conference, demonstrating the unique antitumoral properties of AsiDNA™, a first-in-class DNA Damage Response inhibitor. The data highlights that AsiDNA™ can prevent the regrowth of drug-tolerant persister cells, which are a major barrier in cancer treatment. CEO Judith Greciet emphasized the significance of these findings in combating therapy resistance, paving the way for future combination strategies.
Onxeo, a clinical-stage biotechnology firm, has appointed Bryan Giraudo as an independent member of its Board of Directors, succeeding Thomas Hofstaetter. Giraudo is the COO and CFO of Gossamer Bio and brings extensive financial expertise and a robust network in the U.S. life sciences sector. The Board aims to enhance Onxeo's strategy and development in tumor DNA Damage Response (DDR). Shefali Agarwal, Chairwoman, emphasized Giraudo's skills and international focus will further strengthen the company. His role is expected to be vital for the successful advancement of their lead candidate, AsiDNA.
